{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T15:54:13Z","timestamp":1768924453694,"version":"3.49.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T00:00:00Z","timestamp":1662249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T00:00:00Z","timestamp":1662249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s13346-022-01215-5","type":"journal-article","created":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T18:02:32Z","timestamp":1662314552000},"page":"568-579","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The possibility of angiogenesis inhibition in cutaneous melanoma by bevacizumab-loaded lipid-chitosan nanoparticles"],"prefix":"10.1007","volume":"13","author":[{"given":"Fereshteh","family":"Abdi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elham","family":"Arkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mojtaba","family":"Eidizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elahe","family":"Valipour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahereh","family":"Naseriyeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Younes Hossainy","family":"Gamizgy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamran","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,4]]},"reference":[{"key":"1215_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.suc.2019.09.005","volume":"100","author":"S Carr","year":"2020","unstructured":"Carr S, Smith C, Wernberg J. Epidemiology and risk factors of melanoma. Surg Clin North Am. 2020;100:1\u201312. https:\/\/doi.org\/10.1016\/j.suc.2019.09.005.","journal-title":"Surg Clin North Am"},{"key":"1215_CR2","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jaad.2009.07.039","volume":"62","author":"JP Spanogle","year":"2010","unstructured":"Spanogle JP, Clarke CA, Aroner S, Swetter SM. Risk of second primary malignancies following cutaneous melanoma diagnosis: a population-based study. J Am Acad Dermatol. 2010;62:757\u201367. https:\/\/doi.org\/10.1016\/j.jaad.2009.07.039.","journal-title":"J Am Acad Dermatol"},{"key":"1215_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2147\/vhrm.2006.2.3.213","volume":"2","author":"N Nishida","year":"2006","unstructured":"Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in cancer. Vasc Health Risk Manag. 2006;2:213. https:\/\/doi.org\/10.2147\/vhrm.2006.2.3.213.","journal-title":"Vasc Health Risk Manag"},{"key":"1215_CR4","doi-asserted-by":"crossref","unstructured":"Mahabeleshwar GH, Byzova TV. Angiogenesis in melanoma. Seminars in oncology: Elsevier.\u00a02007:555\u201365.","DOI":"10.1053\/j.seminoncol.2007.09.009"},{"key":"1215_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1080\/15216540252774784","volume":"52","author":"S Kliche","year":"2001","unstructured":"Kliche S, Waltenberger J. VEGF receptor signaling and endothelial function. IUBMB Life. 2001;52:61\u20136. https:\/\/doi.org\/10.1080\/15216540252774784.","journal-title":"IUBMB Life"},{"key":"1215_CR6","doi-asserted-by":"publisher","first-page":"297","DOI":"10.5732\/cjc.012.10319","volume":"32","author":"SA Stacker","year":"2013","unstructured":"Stacker SA, Achen MG. The VEGF signaling pathway in cancer: the road ahead. Chin J Cancer. 2013;32:297. https:\/\/doi.org\/10.5732\/cjc.012.10319.","journal-title":"Chin J Cancer"},{"key":"1215_CR7","first-page":"852","volume":"1","author":"MS Emmett","year":"2011","unstructured":"Emmett MS, Dewing D, Pritchard-Jones RO. Angiogenesis and melanoma-from basic science to clinical trials. Am J Cancer Res. 2011;1:852.","journal-title":"Am J Cancer Res"},{"key":"1215_CR8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10637-008-9125-4","volume":"26","author":"J Tol","year":"2008","unstructured":"Tol J, Cats A, Mol L, Koopman M, Bos M, Van Der Hoeven J, et al. Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. Invest New Drugs. 2008;26:393\u20137.","journal-title":"Invest New Drugs"},{"key":"1215_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2147\/CMAR.S77400","volume":"7","author":"P Economopoulou","year":"2015","unstructured":"Economopoulou P, Kotsakis A, Kapiris I, Kentepozidis N. Cancer therapy and cardiovascular risk: focus on bevacizumab. Cancer Manag Res. 2015;7:133. https:\/\/doi.org\/10.2147\/CMAR.S77400.","journal-title":"Cancer Manag Res"},{"key":"1215_CR10","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006278","volume":"6","author":"M Totzeck","year":"2017","unstructured":"Totzeck M, Mincu RI, Rassaf T. Cardiovascular adverse events in patients with cancer treated with bevacizumab: a meta-analysis of more than 20 000 patients. J Am Heart Assoc. 2017;6: e006278.","journal-title":"J Am Heart Assoc"},{"key":"1215_CR11","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1038\/eye.2008.360","volume":"23","author":"R Rasier","year":"2009","unstructured":"Rasier R, Artunay O, Yuzbasioglu E, Sengul A, Bahcecioglu H. The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension. Eye. 2009;23:1714\u20138. https:\/\/doi.org\/10.1038\/eye.2008.360.","journal-title":"Eye"},{"key":"1215_CR12","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1001\/jama.2008.656","volume":"300","author":"SR Nalluri","year":"2008","unstructured":"Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300:2277\u201385. https:\/\/doi.org\/10.1001\/jama.2008.656.","journal-title":"JAMA"},{"key":"1215_CR13","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s00228-012-1232-7","volume":"68","author":"S Taugourdeau-Raymond","year":"2012","unstructured":"Taugourdeau-Raymond S, Rouby F, Default A, Jean-Pastor M-J. Bevacizumab-induced serious side-effects: a review of the French pharmacovigilance database. Eur J Clin Pharmacol. 2012;68:1103\u20137. https:\/\/doi.org\/10.1007\/s00228-012-1232-7.","journal-title":"Eur J Clin Pharmacol"},{"key":"1215_CR14","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1007\/s00280-013-2155-4","volume":"71","author":"N Letarte","year":"2013","unstructured":"Letarte N, Bressler LR, Villano JL. Bevacizumab and central nervous system (CNS) hemorrhage. Cancer Chemother Pharmacol. 2013;71:1561\u20135. https:\/\/doi.org\/10.1007\/s00280-013-2155-4.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1215_CR15","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/sj.bjc.6605828","volume":"103","author":"A Mailliez","year":"2010","unstructured":"Mailliez A, Baldini C, Van J, Servent V, Mallet Y, Bonneterre J. Nasal septum perforation: a side effect of bevacizumab chemotherapy in breast cancer patients. Br J Cancer. 2010;103:772\u20135. https:\/\/doi.org\/10.1038\/sj.bjc.6605828.","journal-title":"Br J Cancer"},{"key":"1215_CR16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.addr.2007.04.006","volume":"59","author":"M Sch\u00e4fer-Korting","year":"2007","unstructured":"Sch\u00e4fer-Korting M, Mehnert W, Korting H-C. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv Drug Deliv Rev. 2007;59:427\u201343.","journal-title":"Adv Drug Deliv Rev"},{"key":"1215_CR17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ejps.2017.11.023","volume":"112","author":"A Garc\u00eas","year":"2018","unstructured":"Garc\u00eas A, Amaral M, Lobo JS, Silva AC. Formulations based on solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cutaneous use: a review. Eur J Pharm Sci. 2018;112:159\u201367.","journal-title":"Eur J Pharm Sci"},{"key":"1215_CR18","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0928-0987(98)00037-2","volume":"7","author":"M Kirjavainen","year":"1999","unstructured":"Kirjavainen M, Urtti A, Valjakka-Koskela R, Kiesvaara J, M\u00f6nkk\u00f6nen J. Liposome\u2013skin interactions and their effects on the skin permeation of drugs. Eur J Pharm Sci. 1999;7:279\u201386.","journal-title":"Eur J Pharm Sci"},{"key":"1215_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jconrel.2014.02.004","volume":"180","author":"YS Elnaggar","year":"2014","unstructured":"Elnaggar YS, El-Refaie WM, El-Massik MA, Abdallah OY. Lecithin-based nanostructured gels for skin delivery: an update on state of art and recent applications. J Control Release. 2014;180:10\u201324. https:\/\/doi.org\/10.1016\/j.jconrel.2014.02.004.","journal-title":"J Control Release"},{"key":"1215_CR20","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.ijbiomac.2018.05.184","volume":"117","author":"A Ehterami","year":"2018","unstructured":"Ehterami A, Salehi M, Farzamfar S, Vaez A, Samadian H, Sahrapeyma H, et al. In vitro and in vivo study of PCL\/COLL wound dressing loaded with insulin-chitosan nanoparticles on cutaneous wound healing in rats model. Int J Biol Macromol. 2018;117:601\u20139. https:\/\/doi.org\/10.1016\/j.ijbiomac.2018.05.184.","journal-title":"Int J Biol Macromol"},{"key":"1215_CR21","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.colsurfb.2018.11.005","volume":"174","author":"MB Stie","year":"2019","unstructured":"Stie MB, Thoke HS, Issinger O-G, Hochscherf J, Guerra B, Olsen LF. Delivery of proteins encapsulated in chitosan-tripolyphosphate nanoparticles to human skin melanoma cells. Colloids Surf B Biointerfaces. 2019;174:216\u201323. https:\/\/doi.org\/10.1016\/j.colsurfb.2018.11.005.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"1215_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4","volume":"63","author":"P Calvo","year":"1997","unstructured":"Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso M. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci. 1997;63:125\u201332.","journal-title":"J Appl Polym Sci"},{"key":"1215_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.molliq.2021.116655","volume":"339","author":"F Abdi","year":"2021","unstructured":"Abdi F, Arkan E, Mansouri K, Shekarbeygi Z, Barzegari E. Interactions of Bevacizumab with chitosan biopolymer nanoparticles: molecular modeling and spectroscopic study. J Mol Liq. 2021;339: 116655. https:\/\/doi.org\/10.1016\/j.molliq.2021.116655.","journal-title":"J Mol Liq"},{"key":"1215_CR24","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/j.tiv.2010.05.022","volume":"24","author":"P Seyfi","year":"2010","unstructured":"Seyfi P, Mostafaie A, Mansouri K, Arshadi D, Mohammadi-Motlagh H-R, Kiani A. In vitro and in vivo anti-angiogenesis effect of shallot (Allium ascalonicum): a heat-stable and flavonoid-rich fraction of shallot extract potently inhibits angiogenesis. Toxicol In Vitro. 2010;24:1655\u201361. https:\/\/doi.org\/10.1016\/j.tiv.2010.05.022.","journal-title":"Toxicol In Vitro"},{"key":"1215_CR25","doi-asserted-by":"publisher","unstructured":"Cai J, Huang H, Song W, Hu H, Chen J, Zhang L, et al. Preparation and evaluation of lipid polymer nanoparticles for eradicating H. pylori biofilm and impairing antibacterial resistance in vitro. Int J Pharm. 2015;495:728\u201337.\u00a0https:\/\/doi.org\/10.1016\/j.ijpharm.2015.09.055.","DOI":"10.1016\/j.ijpharm.2015.09.055"},{"key":"1215_CR26","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2217\/nnm.09.105","volume":"5","author":"GM Kuesters","year":"2010","unstructured":"Kuesters GM, Campbell RB. Conjugation of bevacizumab to cationic liposomes enhances their tumor-targeting potential. Nanomedicine. 2010;5:181\u201392.","journal-title":"Nanomedicine"},{"key":"1215_CR27","doi-asserted-by":"crossref","unstructured":"Ugurlu N, A\u015f\u0131k MDa, \u00c7akmak HB, Tuncer S, Turk M, \u00c7ag\u02c7\u0131l N, et al. Transscleral delivery of bevacizumab-loaded chitosan nanoparticles. J Biomed Nanotechnol. 2019;15:830\u201338.","DOI":"10.1166\/jbn.2019.2716"},{"key":"1215_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ijpharm.2006.06.036","volume":"324","author":"F Sonvico","year":"2006","unstructured":"Sonvico F, Cagnani A, Rossi A, Motta S, Di Bari M, Cavatorta F, et al. Formation of self-organized nanoparticles by lecithin\/chitosan ionic interaction. Int J Pharm. 2006;324:67\u201373. https:\/\/doi.org\/10.1016\/j.ijpharm.2006.06.036.","journal-title":"Int J Pharm"},{"key":"1215_CR29","doi-asserted-by":"publisher","first-page":"20876","DOI":"10.1007\/s11356-020-08543-4","volume":"27","author":"LR Rodrigues","year":"2020","unstructured":"Rodrigues LR, Jose J. Exploring the photo protective potential of solid lipid nanoparticle-based sunscreen cream containing Aloe vera. Environ Sci Pollut Res. 2020;27:20876\u201388. https:\/\/doi.org\/10.1007\/s11356-020-08543-4.","journal-title":"Environ Sci Pollut Res"},{"key":"1215_CR30","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.ijbiomac.2019.10.113","volume":"150","author":"PS Bakshi","year":"2020","unstructured":"Bakshi PS, Selvakumar D, Kadirvelu K, Kumar N. Chitosan as an environment friendly biomaterial\u2013a review on recent modifications and applications. Int J Biol Macromol. 2020;150:1072\u201383.","journal-title":"Int J Biol Macromol"},{"key":"1215_CR31","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/hrt.2009.180414","volume":"97","author":"I Zachary","year":"2011","unstructured":"Zachary I, Morgan RD. Therapeutic angiogenesis for cardiovascular disease: biological context, challenges, prospects. Heart. 2011;97:181\u20139. https:\/\/doi.org\/10.1136\/hrt.2009.180414.","journal-title":"Heart"},{"key":"1215_CR32","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.survophthal.2012.01.007","volume":"57","author":"JH Chang","year":"2012","unstructured":"Chang JH, Garg NK, Lunde E, Han KY, Jain S, Azar DT. Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol. 2012;57:415\u201329. https:\/\/doi.org\/10.1016\/j.survophthal.2012.01.007.","journal-title":"Surv Ophthalmol"},{"key":"1215_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/biomedicines5020034","volume":"5","author":"M Rajabi","year":"2017","unstructured":"Rajabi M, Mousa SA. The role of angiogenesis in cancer treatment. Biomedicines. 2017;5:34. https:\/\/doi.org\/10.3390\/biomedicines5020034.","journal-title":"Biomedicines"},{"key":"1215_CR34","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.biocel.2015.04.008","volume":"64","author":"V Tarallo","year":"2015","unstructured":"Tarallo V, De Falco S. The vascular endothelial growth factors and receptors family: up to now the only target for anti-angiogenesis therapy. Int J Biochem Cell Biol. 2015;64:185\u20139. https:\/\/doi.org\/10.1016\/j.biocel.2015.04.008.","journal-title":"Int J Biochem Cell Biol"},{"key":"1215_CR35","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/ITT.S134842","volume":"7","author":"B Domingues","year":"2018","unstructured":"Domingues B, Lopes JM, Soares P, Populo H. Melanoma treatment in review Immunotargets Ther. 2018;7:35\u201349. https:\/\/doi.org\/10.2147\/ITT.S134842.","journal-title":"Melanoma treatment in review Immunotargets Ther"},{"key":"1215_CR36","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1039\/C4BM00427B","volume":"3","author":"S Krishnamurthy","year":"2015","unstructured":"Krishnamurthy S, Vaiyapuri R, Zhang L, Chan JM. Lipid-coated polymeric nanoparticles for cancer drug delivery. Biomater Sci. 2015;3:923\u201336. https:\/\/doi.org\/10.1039\/C4BM00427B.","journal-title":"Biomater Sci"},{"key":"1215_CR37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2009.09.004","volume":"62","author":"T Kean","year":"2010","unstructured":"Kean T, Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv Rev. 2010;62:3\u201311. https:\/\/doi.org\/10.1016\/j.addr.2009.09.004.","journal-title":"Adv Drug Deliv Rev"},{"key":"1215_CR38","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.ijbiomac.2019.10.255","volume":"153","author":"M Zahiri","year":"2020","unstructured":"Zahiri M, Khanmohammadi M, Goodarzi A, Ababzadeh S, Farahani MS, Mohandesnezhad S, et al. Encapsulation of curcumin loaded chitosan nanoparticle within poly (\u03b5-caprolactone) and gelatin fiber mat for wound healing and layered dermal reconstitution. Int J Biol Macromol. 2020;153:1241\u201350.","journal-title":"Int J Biol Macromol"},{"key":"1215_CR39","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s12221-017-6690-1","volume":"18","author":"K Divya","year":"2017","unstructured":"Divya K, Vijayan S, George TK, Jisha M. Antimicrobial properties of chitosan nanoparticles: mode of action and factors affecting activity. Fibers Polym. 2017;18:221\u201330.","journal-title":"Fibers Polym"},{"key":"1215_CR40","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.2174\/138161211798194468","volume":"17","author":"J Vinsova","year":"2011","unstructured":"Vinsova J, Vavrikova E. Chitosan derivatives with antimicrobial, antitumour and antioxidant activities-a review. Curr Pharm Des. 2011;17:3596\u2013607.","journal-title":"Curr Pharm Des"},{"key":"1215_CR41","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1007\/s10311-019-00904-x","volume":"17","author":"N Morin-Crini","year":"2019","unstructured":"Morin-Crini N, Lichtfouse E, Torri G, Crini G. Applications of chitosan in food, pharmaceuticals, medicine, cosmetics, agriculture, textiles, pulp and paper, biotechnology, and environmental chemistry. Environ Chem Lett. 2019;17:1667\u201392. https:\/\/doi.org\/10.1007\/s10311-019-00904-x.","journal-title":"Environ Chem Lett"},{"key":"1215_CR42","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1002\/jbm.a.36424","volume":"106","author":"P Badiee","year":"2018","unstructured":"Badiee P, Varshochian R, Rafiee-Tehrani M, Abedin Dorkoosh F, Khoshayand MR, Dinarvand R. Ocular implant containing bevacizumab-loaded chitosan nanoparticles intended for choroidal neovascularization treatment. J Biomed Mater Res A. 2018;106:2261\u201371. https:\/\/doi.org\/10.1002\/jbm.a.36424.","journal-title":"J Biomed Mater Res A"},{"key":"1215_CR43","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.colsurfb.2007.04.009","volume":"59","author":"Q Gan","year":"2007","unstructured":"Gan Q, Wang T. Chitosan nanoparticle as protein delivery carrier\u2014systematic examination of fabrication conditions for efficient loading and release. Colloids Surf B Biointerfaces. 2007;59:24\u201334.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"1215_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-03959-4","volume":"7","author":"F Sousa","year":"2017","unstructured":"Sousa F, Cruz A, Fonte P, Pinto IM, Neves-Petersen MT, Sarmento B. A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles. Sci Rep. 2017;7:1\u201313.","journal-title":"Sci Rep"},{"key":"1215_CR45","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.3390\/ma3031928","volume":"3","author":"R Solaro","year":"2010","unstructured":"Solaro R, Chiellini F, Battisti A. Targeted delivery of protein drugs by nanocarriers. Materials. 2010;3:1928\u201380.","journal-title":"Materials"},{"key":"1215_CR46","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jconrel.2004.10.017","volume":"102","author":"TD Dziubla","year":"2005","unstructured":"Dziubla TD, Karim A, Muzykantov VR. Polymer nanocarriers protecting active enzyme cargo against proteolysis. J Control Release. 2005;102:427\u201339. https:\/\/doi.org\/10.1016\/j.jconrel.2004.10.017.","journal-title":"J Control Release"},{"key":"1215_CR47","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.2147\/IJN.S195504","volume":"14","author":"J-G Sun","year":"2019","unstructured":"Sun J-G, Jiang Q, Zhang X-P, Shan K, Liu B-H, Zhao C, et al. Mesoporous silica nanoparticles as a delivery system for improving antiangiogenic therapy. Int J Nanomedicine. 2019;14:1489.","journal-title":"Int J Nanomedicine"},{"key":"1215_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2019.107697","volume":"185","author":"IL de Red\u00edn","year":"2019","unstructured":"de Red\u00edn IL, Boiero C, Recalde S, Ag\u00fceros M, Allemandi D, Llabot JM, et al. In vivo effect of bevacizumab-loaded albumin nanoparticles in the treatment of corneal neovascularization. Exp Eye Res. 2019;185: 107697.","journal-title":"Exp Eye Res"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-022-01215-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-022-01215-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-022-01215-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T19:19:49Z","timestamp":1672168789000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-022-01215-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,4]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1215"],"URL":"https:\/\/doi.org\/10.1007\/s13346-022-01215-5","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,4]]},"assertion":[{"value":"20 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the animal procedures were performed in accordance with the guidelines for the care and use of laboratory animals; the present study has been approved by the Medical Ethic Committee of the Kermanshah University of Medical Sciences (Reference number IR.KUMS.REC.1398.1111).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors have approved that the submitted works are original, and the paper has not been published and is not being considered for publication elsewhere.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declared no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}